KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer.

Keitaro Shimozaki Eiji ShinozakiNoriko YamamotoYu ImamuraHiroki OsumiIzuma NakayamaTakeru WakatsukiAkira OokiDaisuke TakahariMariko OguraKeisho ChinMasayuki WatanabeKensei Yamaguchi

Published in: Journal of cancer research and clinical oncology (2022)

KRAS mutation was an independent prognostic factor for poor survival and might predict insufficient trastuzumab efficacy, whereas KRAS amplification showed no prognostic significance during trastuzumab treatment. Further investigations are warranted to confirm the predictive value of KRAS status in HER2-positive AGC.

Keyphrases

poor prognosis
wild type
prognostic factors
epidermal growth factor receptor
long non coding rna
metastatic breast cancer
tyrosine kinase
radiation therapy
lymph node
rectal cancer